Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by MetzGERon Sep 02, 2023 1:37am
212 Views
Post# 35617258

Simon Ma

Simon Ma

Simon Ma didnt Leave the company because he wasnt confident with the company. NO, unfortunately he died because of Terminal Illness :((

"due to the recent demise of the Company’s Chief Financial Officer, Simon Ma, after a debilitating terminal illness and because Mr. Ma’s successor, who was only just appointed (on August 16, 2023), will need time to settle in to his new role and prepare the Interim Filings."
https://ceo.ca/content/sedar/RP-2023-09-02-news-release-english-22d4.pdf


@Ingiboy: Whi Said that the Deadline will end on 31. August? I think it was only you? Why you Are so frustrated now? We will hear in the AGM about the ongoing Dispute with Shiseido.
as we all are confident that Replicel has the stronger Case and Shiseido Breached the contract - there is nothing to worry. We will Win.
furthermore Andrew has 17.000.000 Shares and Jamie has 11.000.000 Shares - they Are Big investors with Big Knowledge about investing in Companys. They could have choose other Companys to invest But they choose Replicel and invested a huge amount of money. It is because Replicel has this Strong Case and the Heavy upside Potentials - Investors Love that !

<< Previous
Bullboard Posts
Next >>